Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma
Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology 2015, 17: 1344-1355. PMID: 25754088, PMCID: PMC4578577, DOI: 10.1093/neuonc/nov015.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBrain NeoplasmsChildChild, PreschoolComparative Genomic HybridizationDNA Copy Number VariationsFemaleGene Expression ProfilingGenome-Wide Association StudyGenotypeGlioblastomaHumansInfantIsocitrate DehydrogenaseMaleMiddle AgedMutationProspective StudiesPTEN PhosphohydrolaseTumor Suppressor Protein p53Young AdultConceptsClinical trialsBrain tumorsGlioblastoma patientsClinical settingClinical Laboratory Improvement AmendmentsParaffin-embedded samplesWhole-genome array comparative genomic hybridizationWhole gene sequencingTherapeutic trialsWhole-genome copy numberClinical testing resultsPatientsClinical diagnosisMutation profilingIntegral biomarkerArray comparative genomic hybridizationGlioblastomaClinical implementationTrialsComparative genomic hybridizationTumor suppressor inactivationCopy numberTumorsFFPE samplesDiagnostic laboratories